Lbp Am Sa Has $21.27 Million Stock Position in Cencora, Inc. (NYSE:COR)

LBP AM SA trimmed its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 3.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 76,495 shares of the company's stock after selling 2,855 shares during the period. LBP AM SA's holdings in Cencora were worth $21,272,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Cornerstone Planning Group LLC increased its stake in shares of Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock worth $26,000 after buying an additional 48 shares during the last quarter. Hoey Investments Inc. acquired a new position in Cencora in the first quarter worth about $28,000. Banque Transatlantique SA bought a new stake in Cencora in the fourth quarter valued at about $29,000. SBI Securities Co. Ltd. acquired a new stake in Cencora during the fourth quarter valued at approximately $30,000. Finally, Vermillion Wealth Management Inc. acquired a new stake in Cencora during the fourth quarter valued at approximately $38,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Cencora stock traded down $2.14 during mid-day trading on Thursday, hitting $298.02. 275,775 shares of the company's stock traded hands, compared to its average volume of 1,641,454. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The company has a market cap of $57.76 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 1.48 and a beta of 0.57. The firm has a 50 day moving average price of $291.72 and a 200 day moving average price of $268.75. The company has a quick ratio of 0.52, a current ratio of 0.87 and a debt-to-equity ratio of 6.01.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. Cencora's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.80 EPS. On average, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.74%. Cencora's dividend payout ratio (DPR) is 25.52%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on COR. Bank of America upped their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Morgan Stanley set a $288.00 target price on shares of Cencora in a report on Tuesday, April 15th. Robert W. Baird lifted their price target on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Finally, Citigroup raised their target price on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, Cencora presently has an average rating of "Moderate Buy" and a consensus target price of $306.33.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total value of $4,266,106.98. Following the sale, the chairman directly owned 311,913 shares in the company, valued at approximately $91,271,982.06. The trade was a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the sale, the chief executive officer directly owned 47,582 shares of the company's stock, valued at approximately $13,766,900.06. This represents a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,127 shares of company stock valued at $9,812,296 in the last ninety days. Company insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.